Literature DB >> 24478179

Prognostic factors in squamous cell lip carcinoma treated with high-dose-rate brachytherapy.

Jose-Luis Guinot1, Leoncio Arribas, Juan B Vendrell, Miguel Santos, Maria I Tortajada, Alejandro Mut, Julia Cruz, Jose L Mengual, Maria L Chust.   

Abstract

BACKGROUND: The purpose of this study was for us to present our analysis of the results and prognostic factors in squamous lip carcinoma treated with high-dose-rate (HDR) brachytherapy.
METHODS: From 1999 to 2010, 102 patients were treated with HDR-brachytherapy, 54 with T1, 33 with T2, and 15 with T4. Eight cases were N+. Twenty-one patients were treated with surgery plus brachytherapy because of close/positive margins. Nine fractions of 5 Gy were given over 5 days in 67% of the patients. Elective neck treatment was performed in 23 cases.
RESULTS: The 10-year actuarial local control was 94.6%, nodal regional control was 88.6%, disease-free survival was 84.6%, and cause-specific survival was 93.2%. In the univariate analysis, T4 tumors had higher risk of local failure and T2 of regional relapse. In the multivariate analysis, skin involvement was the only significant factor for tumor progression.
CONCLUSION: HDR-brachytherapy yields excellent local control rates. Skin involvement increases the risk of local and cervical recurrence. Elective neck treatment should be done in T2 to T4 tumors or with skin or commissure involvement.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  brachytherapy; high-dose-rate; lip carcinoma; prognostic factors; squamous cell

Mesh:

Year:  2014        PMID: 24478179     DOI: 10.1002/hed.23529

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  7 in total

1.  Adjuvant interstitial three-dimensional pulse-dose-rate-brachytherapy for lip squamous cell carcinoma after surgical resection.

Authors:  Artur Jan Chyrek; Grzegorz Mikołaj Biele Bielęda; Wojciech Maria Burchardt; Adam Chicheł; Piotr Andrzej Wojcieszek
Journal:  J Contemp Brachytherapy       Date:  2019-04-29

Review 2.  Is There Still a Place for Brachytherapy in the Modern Treatment of Early-Stage Oral Cancer?

Authors:  Luboš Tuček; Milan Vošmik; Jiří Petera
Journal:  Cancers (Basel)       Date:  2022-01-03       Impact factor: 6.639

3.  ORIFICE (Interventional Radiotherapy for Face Aesthetic Preservation) Study: Results of Interdisciplinary Assessment of Interstitial Interventional Radiotherapy (Brachytherapy) for Periorificial Face Cancer.

Authors:  Luca Tagliaferri; Ilaria Giarrizzo; Bruno Fionda; Mario Rigante; Monica Maria Pagliara; Calogero Casà; Claudio Parrilla; Valentina Lancellotta; Elisa Placidi; Alessandra Salvati; Gabriella Macchia; Stefano Gentileschi; Maria Antonietta Blasi; Alessio Giuseppe Morganti; Francesco Bussu; Ketty Peris; Gaetano Paludetti; Vincenzo Valentini
Journal:  J Pers Med       Date:  2022-06-24

4.  High-dose-rate brachytherapy (interventional radiotherapy) in lip carcinoma with rigid needles: a simple technique with excellent results.

Authors:  Jose Luis Guinot; Maria Isabel Tortajada; Miguels Angel Santos; Maria Luisa Chust; Leoncio Arribas
Journal:  J Contemp Brachytherapy       Date:  2022-06-30

Review 5.  Age Is Not a Limiting Factor in Interventional Radiotherapy (Brachytherapy) for Patients with Localized Cancer.

Authors:  Valentina Lancellotta; György Kovács; Luca Tagliaferri; Elisabetta Perrucci; Giuseppe Colloca; Vincenzo Valentini; Cynthia Aristei
Journal:  Biomed Res Int       Date:  2018-01-21       Impact factor: 3.411

6.  High dose rate interstitial brachytherapy for early stage lip cancer using customized dental spacer.

Authors:  Koji Masui; Hideya Yamazaki; Gen Suzuki; Daisuke Shimizu; Kanako Kawabata; Naoki Noguchi; Tadashi Takenaka; Ken Yoshida; Naoya Murakami; Masayuki Naito; Toshiro Yamamoto; Narisato Kanamura; Satoshi Komori; Akifumi Oshita; Jun Asai; Kei Yamada
Journal:  J Radiat Res       Date:  2020-05-22       Impact factor: 2.724

7.  Pulsed Dose Rate Brachytherapy of Lip Carcinoma: Clinical Outcome and Quality of Life Analysis.

Authors:  Radouane El Ayachy; Roger Sun; Kanta Ka; Adrien Laville; Anne-Sophie Duhamel; Anne Tailleur; Isabelle Dumas; Sophie Bockel; Sophie Espenel; Pierre Blanchard; Yungan Tao; Stéphane Temam; Antoine Moya-Plana; Christine Haie-Meder; Cyrus Chargari
Journal:  Cancers (Basel)       Date:  2021-03-19       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.